Company news
Penumbra, Inc. (NYSE:PEN) news
Penumbra, Inc. news releases on 6ix. Latest, Jul 30, 2026: Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Press releases & updates
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
July 30, 2026
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
July 22, 2026
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
July 7, 2026
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
June 15, 2026
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
June 11, 2026
Penumbra, Inc. Reports First Quarter 2026 Financial Results
May 6, 2026
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
April 13, 2026
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
April 7, 2026
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
Boston Scientific announces results for fourth quarter and full year 2025
February 4, 2026
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
January 15, 2026
Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
November 19, 2025
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
November 5, 2025
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
November 3, 2025
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
October 27, 2025
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
October 8, 2025
Penumbra, Inc. Names Shruthi Narayan as Company President
August 27, 2025
Penumbra, Inc. to Present at Upcoming Investor Conferences
August 20, 2025
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
July 30, 2025
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
July 29, 2025
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025
July 1, 2025
Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial
June 16, 2025
Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization
June 5, 2025
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference
April 29, 2025
Penumbra, Inc. Reports First Quarter 2025 Financial Results
April 23, 2025
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025
April 3, 2025
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits
April 2, 2025
Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors
February 21, 2025
Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
February 18, 2025